In all fairness, @Erneter, based on what Steven states from 31:20 to 32:47 about partnerships, I think you have overlooked the differentiation between the two platforms. Yes, because of tightening of money in the industry, the potential for partners in OmniCAR at the present juncture has reduced. However, CellPryme has an advantage because it does not require a prospective partner to redesign a clinical trial. OmniCAR was always likely going to be "lets wait and see how OmniCAR performs in PTX trials first". CellPryme (and particularly CP-M) is far more straight forward and readily applicable and doesn't require FDA approval or trial redesigns or injections of investment.... and is, therefore, still viable for licensing prospects in this environment. To refer to either as duds is simply wrong, IMO. Glad to read that you are positive on the more immediate catalyst of PTX100, though!
PTX Price at posting:
10.5¢ Sentiment: Buy Disclosure: Held
